Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)‘s stock had its “buy” rating reaffirmed by Guggenheim in a note issued to investors on Wednesday. They presently have a $80.00 price target on the stock. Guggenheim’s price target would suggest a potential upside of 76.76% from the company’s current price.

TEVA has been the subject of a number of other reports. Jefferies Group reduced their price objective on shares of Teva Pharmaceutical Industries from $72.00 to $69.00 and set a “buy” rating for the company in a research note on Thursday, July 14th. RBC Capital Markets set a $71.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research note on Sunday, September 11th. Mizuho reaffirmed a “buy” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, July 25th. Bank of America Corp. set a $72.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research note on Saturday. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $66.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Tuesday, August 16th. Seven investment analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $67.14.

Teva Pharmaceutical Industries (NYSE:TEVA) traded down 0.55% during midday trading on Wednesday, reaching $45.01. 2,669,844 shares of the company’s stock traded hands. Teva Pharmaceutical Industries has a 52 week low of $44.92 and a 52 week high of $66.55. The company’s 50-day moving average price is $50.75 and its 200 day moving average price is $52.69. The stock has a market capitalization of $41.14 billion, a price-to-earnings ratio of 30.07 and a beta of 0.74.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.20 by $0.05. Teva Pharmaceutical Industries had a net margin of 7.56% and a return on equity of 17.77%. The company earned $5 billion during the quarter, compared to the consensus estimate of $4.86 billion. During the same period in the prior year, the company earned $1.43 EPS. Teva Pharmaceutical Industries’s revenue was up 1.4% on a year-over-year basis. On average, equities research analysts expect that Teva Pharmaceutical Industries will post $5.26 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Monday, August 22nd were issued a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, August 18th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.00%. Teva Pharmaceutical Industries’s payout ratio is presently 77.85%.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Eqis Capital Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 18.3% in the third quarter. Eqis Capital Management Inc. now owns 39,047 shares of the company’s stock worth $1,797,000 after buying an additional 6,047 shares during the last quarter. Washington Trust Bank boosted its position in shares of Teva Pharmaceutical Industries by 2.7% in the third quarter. Washington Trust Bank now owns 2,232 shares of the company’s stock worth $103,000 after buying an additional 58 shares during the last quarter. Beacon Financial Group boosted its position in shares of Teva Pharmaceutical Industries by 21.4% in the third quarter. Beacon Financial Group now owns 9,579 shares of the company’s stock worth $443,000 after buying an additional 1,689 shares during the last quarter. Carnick & Kubik Group LLC bought a new position in shares of Teva Pharmaceutical Industries during the second quarter worth about $1,624,000. Finally, Northwestern Mutual Wealth Management Co. boosted its position in shares of Teva Pharmaceutical Industries by 17.5% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 21,940 shares of the company’s stock worth $1,102,000 after buying an additional 3,270 shares during the last quarter. 63.35% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.